PDF herunterladen
Geburtshilfe Frauenheilkd 2015; 75(12): 1243-1249
DOI: 10.1055/s-0035-1558184
Review
GebFra Science
Georg Thieme Verlag KG Stuttgart · New York

Fertility Protection in Female Oncology Patients: How Should Patients Be Counseled?

Fertilitätsprotektion von onkologischen Patientinnen: Wie sollten die Patientinnen beraten werden?
S. Findeklee
1   Gynecology and Obstetrics, Universitätsklinikum Erlangen, Erlangen
,
L. Lotz
1   Gynecology and Obstetrics, Universitätsklinikum Erlangen, Erlangen
,
K. Heusinger
1   Gynecology and Obstetrics, Universitätsklinikum Erlangen, Erlangen
,
I. Hoffmann
2   Gynecologic Endocrinology and Reproductive Medicine, Universitätsklinikum Erlangen, Erlangen
,
R. Dittrich
2   Gynecologic Endocrinology and Reproductive Medicine, Universitätsklinikum Erlangen, Erlangen
,
M. W. Beckmann
1   Gynecology and Obstetrics, Universitätsklinikum Erlangen, Erlangen
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 21. Juli 2015
revised 22. August 2015

accepted 25. August 2015

Publikationsdatum:
21. Dezember 2015 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Protecting the fertility of patients with oncologic disease is becoming more and more important, as fulfilling the wish to have children is increasingly occurring at a later stage in life and long-term survival rates after cancer are continuing to improve. A number of fertility-preserving options exist. In addition to techniques which have been around for some time such as medical ovarian suppression, ovarian transposition, and organ-preserving surgery, there are other, more recent, innovative methods which have developed over the last few years such as cryopreservation of oocytes or ovarian tissue transplantation after completing cancer therapy. As every procedure has its specific advantages and disadvantages, informed patient consent is essential. The physicianʼs aim must be to select the optimal procedure for each patient. The extent of patientsʼ information about the options to preserve fertility in women with oncologic disease remains limited. One of the main reasons for this is that clinicians are not sure how to inform patients about existing procedures and methods. The aim of this review article is to provide help in clinical practice.

Zusammenfassung

Dem Fertilitätserhalt bei Krebserkrankungen kommt eine immer größere Bedeutung zu, da sich die Erfüllung des Kinderwunschs zunehmend in spätere Lebensphasen verschiebt und das Langzeitüberleben bei Krebs steigt. Es steht eine Vielzahl fertilitätsprotektiver Maßnahmen zur Verfügung. Neben den seit längerer Zeit praktizierten Verfahren der medikamentösen Ovarsuppression, der Transposition der Eierstöcke und der organerhaltenden Chirurgie haben sich in den letzten Jahren die innovativen Methoden Kryokonservierung von Eizellen und Eierstockgewebe mit der späteren Transplantation nach Therapieabschluss etabliert. Jedes Vorgehen hat seine spezifischen Vor- und Nachteile, über die ärztlicherseits aufgeklärt werden muss. Letztendlich geht es darum, für jede Patientin das optimale Verfahren auszuwählen. Immer noch ist die Aufklärungsrate bez. Fertilitätserhalt bei Frauen mit onkologischen Erkrankungen sehr gering. Als wesentlicher Grund hierfür gilt auch, dass bei den Behandelnden eine Unsicherheit darüber besteht, wie sie Patientinnen über Methoden aufklären sollen. Der hier vorgestellte Review-Artikel soll eine Unterstützung im klinischen Alltag bieten.

Key words

fertility preservation - cancer - wish for a child

Schlüsselwörter

Fertilitätserhalt - Krebserkrankung - Kinderwunsch

Supporting Information

 

  • References

  • 1 Statistisches Bundesamt. Alter bei der Geburt des ersten Kinds in Deutschland.. Online: https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Geburten/Tabellen/GeburtenMutterAlterBundeslaender.html last access: 30.04.2015
    PubMedGoogle Scholar
  • 2 Menken J, Trussell J, Larsen U. Age and infertility. Science 1986; 233: 1389-1394
    CrossrefPubMedGoogle Scholar
  • 3 Mattle V, Behringer K, Engert A et al. Female fertility after cytotoxic therapy-protection of ovarian function during chemotherapy of malignant and non-malignant diseases. Eur J Haematol Suppl 2005; 66: 77-82
    PubMedGoogle Scholar
  • 4 Anderson RA, Wallace WH, Baird DT. Ovarian cryopreservation for fertility preservation: indications and outcomes. Reproduction 2008; 136: 681-689
    CrossrefPubMedGoogle Scholar
  • 5 Lee MC, Gray J, Han HS et al. Fertility and reproductive considerations in premenopausal patients with breast cancer. Cancer Control 2010; 17: 162-172
    PubMedGoogle Scholar
  • 6 Li A, Pasternak M, Duke C et al. The effect of practitioner education on fertility preservation awareness, perception and clinical practice. Obstet Gynecol 2015; 125: 8-9
    PubMedGoogle Scholar
  • 7 Dnistrian AM, Schwartz MK, Fraccchia AA et al. Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer 1993; 51: 803-807
    PubMedGoogle Scholar
  • 8 Gonfloni S, Di Tella L, Caldarola S et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med 2009; 15: 1179-1185
    CrossrefPubMedGoogle Scholar
  • 9 Critchley HO, Wallace WH. Impact of cancer treatment on uterine function. J Nat Can Inst 2005; 34: 64-68
    PubMedGoogle Scholar
  • 10 Ben-Aharon I, Bar-Joseph H, Tzarfaty G et al. Doxorubicin-induced ovarian toxicity. Reprod Biol Endocrinol 2010; 4: 8-20
    PubMedGoogle Scholar
  • 11 Hart R. Preservation of fertility in adults and children diagnosed with cancer. BMJ 2008; 337: a2045
    CrossrefPubMedGoogle Scholar
  • 12 Abusief ME, Missmer SA, Ginsburg ES et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 2010; 116: 791-798
    CrossrefPubMedGoogle Scholar
  • 13 Parulekar WR, Day AG, Ottaway JA et al. National Cancer Institute of Canada Clinical Trials Group. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study – NCIC CTG MA. J Clin Oncol 2005; 23: 6002-6008
    CrossrefPubMedGoogle Scholar
  • 14 van der Kaaij MA, Heutte N, Meijnders P et al. Premature ovarian failure and fertility in long-term survivors of Hodgkinʼs lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe dʼEtude des Lymphomes de lʼAdulte Cohort Study. J Clin Oncol 2012; 30: 291-299
    CrossrefPubMedGoogle Scholar
  • 15 Elis A, Tevet A, Yerushalmi R et al. Fertility status among women treated for aggressive non-Hodgkinʼs lymphoma. Leuk Lymphoma 2006; 47: 623-627
    CrossrefPubMedGoogle Scholar
  • 16 Pérez-Fidalgo JA, Roselló S, García-Garré E et al. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline based regimens. Breast Cancer Res Treat 2010; 120: 245-251
    CrossrefPubMedGoogle Scholar
  • 17 Schultheis B, Nijmeijer BA, Yin H et al. Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res 2012; 36: 271-274
    CrossrefPubMedGoogle Scholar
  • 18 Witzel ID, Müller V, Harps E et al. Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol 2008; 19: 191-192
    PubMedGoogle Scholar
  • 19 Newman H, Finger PT, Chin KJ et al. Systemic bevacizumab (avastin) for exudative retinal detachment secondary to choroidal melanoma. Eur J Ophthalmol 2011; 21: 796-801
    CrossrefPubMedGoogle Scholar
  • 20 Genetech. U.S. BL125085, Supplement. Bevacizumab Genentech, Inc.; 2011
    Google Scholar
  • 21 Park JY, Joo WD, Chang SJ et al. Long-term outcomes after fertility-sparing laparoscopic radical trachelectomy in young women with early-stage cervical cancer: an Asan Gynecologic Cancer Group (AGCG) study. J Surg Oncol 2014; 110: 252-257
    CrossrefPubMedGoogle Scholar
  • 22 Hauerberg L, Høgdall C, Loft A et al. Vaginal radical trachelectomy for early stage cervical cancer. Results of the Danish National Single Center Strategy. Gynecol Oncol 2015; 138: 304-310
    CrossrefPubMedGoogle Scholar
  • 23 Loizzi V, Selvaggi L, Leone L et al. Borderline epithelial tumors of the ovary: experience of 55 patients. Oncol Lett 2015; 9: 912-914
    PubMedGoogle Scholar
  • 24 Alvarez RM, Vazquez-Vicente D. Fertility sparing treatment in borderline ovarian tumors. Ecancermedicalscience 2015; 9: 507
    PubMedGoogle Scholar
  • 25 Zapardiel I, Diestro MD, Aletti G. Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes. Eur J Surg Oncol 2014; 40: 387-393
    CrossrefPubMedGoogle Scholar
  • 26 Lee SJ, Schover L, Partridge AH et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917-2931
    CrossrefPubMedGoogle Scholar
  • 27 Edgar DH, Gook DA. A critical appraisal of cryopreservation (slow cooling versus vitrification) of human oocytes and embryos. Hum Reprod Update 2012; 18: 536-554
    CrossrefPubMedGoogle Scholar
  • 28 Morice P, Thiam-Ba R, Castaigne D et al. Fertility results after ovarian transposition for pelvic malignancies treated by external irradiation or brachytherapy. Hum Reprod 1998; 13: 660-663
    CrossrefPubMedGoogle Scholar
  • 29 Shou H, Chen Y, Chen Z et al. Laparoscopic ovarian transposition in young women with cervical squamous cell carcinoma treated by primary pelvic irradiation. Eur J Gynaecol Oncol 2015; 36: 25-29
    PubMedGoogle Scholar
  • 30 Beck-Fruchter R, Weiss A, Shalec E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update 2008; 14: 553-561
    CrossrefPubMedGoogle Scholar
  • 31 Blumenfeld Z, von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 2008; 14: 543-552
    CrossrefPubMedGoogle Scholar
  • 32 Dittrich R, Maltaris T, Hoffmann I et al. Fertility preservation in cancer patients. Minerva Ginecol 2010; 62: 63-80
    PubMedGoogle Scholar
  • 33 Loren AW, Mangu PB, Beck LN et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2013; 31: 2500-2510
    CrossrefPubMedGoogle Scholar
  • 34 Von Wolff M, Thaler CJ, Frambach T et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril 2009; 92: 1360-1365
    CrossrefPubMedGoogle Scholar
  • 35 Whittingham DG. In-vitro fertilization, embryo transfer and storage. Br Med Bull 1979; 35: 105-111
    PubMedGoogle Scholar
  • 36 Sanchez M, Novella-Maestre E, Teruel J et al. The Valencia Programme for Fertility Preservation. Clin Transl Oncol 2008; 10: 433-438
    CrossrefPubMedGoogle Scholar
  • 37 Herraiz S, Novella-Maestre E, Rodriguez B et al. Improving ovarian tissue cryopreservation for oncologic patients: slow freezing versus vitrification, effect of different procedures and devices. Fertil Steril 2014; 101: 775-784
    CrossrefPubMedGoogle Scholar
  • 38 Cobo A, Vajta G, Remohi J. Vitrification of human mature oocytes in clinical practice. Reprod Biomed Online 2009; 19: 4385
    PubMedGoogle Scholar
  • 39 Smith GD, Serafini PC, Fioravanti J et al. Prospective randomized comparison of human oocyte cryopreservation with slow-rate freezing or vitrification. Fertil Steril 2010; 94: 2088-2095
    CrossrefPubMedGoogle Scholar
  • 40 Cobo A, Meseguer M, Remohi J et al. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod 2010; 25: 2239-2246
    CrossrefPubMedGoogle Scholar
  • 41 Donnez J, Dolmans MM, Demylle D et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 364: 1405-1410
    CrossrefPubMedGoogle Scholar
  • 42 Oktay K, Karlikaya G. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N Engl J Med 2000; 342: 1919
    CrossrefPubMedGoogle Scholar
  • 43 Krishnakumar S, Tambe P. Laparoscopic entry: a review of techniques, technologies and complications. J Gynecol Endosc Surg 2009; 1: 4-11
    PubMedGoogle Scholar
  • 44 Donnez J, Dolmans MM, Pellicer A et al. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. Fertil Steril 2013; 99: 1503-1513
    CrossrefPubMedGoogle Scholar
  • 45 Donnez J, Dolmans MM. Fertility preservation in women. Nat Rev Endocrinol 2013; 9: 735-749
    CrossrefPubMedGoogle Scholar
  • 46 Stern CJ, Gook D, Hale LG et al. Delivery of twins following heterotopic grafting of frozen-thawed ovarian tissue. Hum Reprod 2014; 29: 1828
    PubMedGoogle Scholar
  • 47 Lawrenz B, Jauckus J, Kupka MS et al. Fertility preservation in > 1,000 patients: patientʼs characteristics, spectrum, efficacy and risks of applied preservation techniques. Arch Gynecol Obstet 2011; 283: 651-656
    CrossrefPubMedGoogle Scholar
  • 48 Corbett S, Shmorgun D, Claman P et al. Reproductive Endocrinology Infertility Committee. The prevention of ovarian hyperstimulation syndrome. J Obstet Gynaecol Can 2014; 36: 1024-1036
    PubMedGoogle Scholar
  • 49 Rosendahl M, Andersen MT, Ralfkiaer E et al. Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukaemia. Fertil Steril 2010; 94: 2186-2190
    CrossrefPubMedGoogle Scholar
  • 50 Arav A, Gavish Z, Elami A et al. Ovarian function 6 years after cryopreservation and transplantation of whole sheep ovaries. Reprod Biomed Online 2010; 20: 48-52
    CrossrefPubMedGoogle Scholar
  • 51 Donnez J, Dolmans MM, Pellicer A et al. Fertility preservation for age-related fertility decline. Lancet 2015; 385: 506-507
    PubMedGoogle Scholar
  • 52 Nekkebroeck J, Stoop D, Devroey P. O-036 A preliminary profile of women opting for oocyte cryopreservation for non-medical reasons. Hum Reprod 2010; 25: i15-i16
    PubMedGoogle Scholar
  • 53 Stoop D, Maes E, Polyzos NP et al. Oocyte banking for anticipated gamete exhaustion (AGE) is a preventive intervention, neither social nor nonmedical. Reprod Biomed Online 2014; 28: 548-551
    CrossrefPubMedGoogle Scholar
  • 54 Rosendahl M, Greve T, Andersen CY. The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature. J Assist Reprod Genet 2013; 30: 11-24
    CrossrefPubMedGoogle Scholar
  • 55 Lotz L, Montag M, Van der Ven H et al. Xenotransplantation of cryopreserved ovarian tissue from patients with ovarian tumors into SCID mice–no evidence of malignant cell contamination. Fertil Steril 2011; 95: 2612-2614
    CrossrefPubMedGoogle Scholar
  • 56 Rosendahl M, Andersen MT, Ralfkiaer E et al. Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Fertil Steril 2010; 94: 2186-2190
    CrossrefPubMedGoogle Scholar
  • 57 Carcio HA ed. Management of the infertile Woman. Philadelphia: Lippincott; 1998
    Google Scholar